Conmed Healthcare (NASDAQ: CONM) has been relatively unchanged at $3.27 with no volume. It has a market capitalization of $41.97 million and a P/E ratio of 20.83 for the past 12 trailing months. Company announced today that it has signed a full service agreement with the city of Alexandria, Virginia for an initial five-year term with options for two year renewals at the cities preferred option, totaling up to nine years to provide correctional healthcare services for the Alexandria adult detention Center. The first year of the contract is expected to generate annual revenues for comment of $2 million with the potential to generate up to 18 million over the full nine-year contract term.
Conmed Healthcare Management, Inc. (Conmed) provides healthcare services to county and municipal detention centers across the United States. The Company provides a range of healthcare services for inmates in county and municipal facilities under contract with the counties served. Correctional healthcare services include a range of services that support the care of inmates detained in county detention centers. Correctional healthcare services include general healthcare services, acute care services, surgical services, laboratory services, IV therapy, Electrocardiogram (EKG's), diagnostic imaging/radiology, electronic medical records, dialysis services, durable medical equipment, hospital services, mental health services, pharmacy, physical and occupational therapy, dental services and electronic medication administration records.
Ceco Environmental Corp. (NASDAQ: CECE) has gained 2.70% or $0.15 to settle at $5.70 a share with light volume of 13,115 shares.the stock has an average volume of 28,260 shares with a market cap of $82 million. Company today announced that it has new orders which should total in an estimate of 3.9 million dollars in proceeds.
CECO Environmental Corp. (CECO) operate as a provider of air pollution control products and services through four principal product groups: its Contracting/Services Group, which produces air pollution control and industrial ventilation systems, its Equipment Group, which produces various types of air pollution control equipment, its Parts Group, which manufactures products used by the Company and other air pollution control companies and contractors, and its Engineering Group, which provides industrial ventilation engineering and source emission testing services.
Somaxon Pharm. (NASDAQ: SOMX) has gained 3.05% or nine cents to settle at $3.04 a share with an increased volume of 1,673,822 shares, which is twice the average volume of its 883,000 shares. The company has a market capitalization of $107 million. It announced today that it has engaged its contract salesforce partner Publicist Touch Point Solutions to start recruiting and deploying for Saul Markson an additional 35 sales reps that will exclusively promote Silenor.
Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. On March 18, 2010, the food and drug administration (FDA) notified the Company that it approved its New Drug Application (NDA) for Silenor (doxepin) three mlilligram and six milligram tablets for the treatment of insomnia characterized by difficulty with sleep maintenance.
Geomet (NASDAQ: GMET) has climbed 1.52% or two cents to settle at $1.34 with a moderate volume of 69,529 shares and an average volume of hundred and 24,051 shares. The company has a market capitalization of $52.87 million. Taoday it announced that its estimate for natural gas reserves as of December 31, 2010 prepared by the McNaughton petroleum engineers totaled 216,000,000,000 cubic feet, which is a 7% increase y.o.y. of 2009 reserves. The company replaced 200% of its net gas sales volume for the year.
GeoMet, Inc. is an independent energy company. The Company is primarily engaged in the exploration for and development and production of natural gas from coal seams (coalbed methane or CBM) and non-conventional shallow gas. Its principal operations and producing properties are located in the Cahaba Basin in Alabama, and the Central Appalachian Basin in West Virginia and Virginia.
Rosetta Genomics. (NASDAQ: ROSG) has lost 2.17% or two cents a share to settle at $.81 with a moderate volume of 70,750 shares traded by the end of Tuesday. The company's average volume is 96,130 shares with a market cap of $13.71 million. Rosetta Genomics today announced that it received NASDAQ extension for continuous listing due to the fact that it has been below one dollar a share for quite some time as it risked the factor of being delisted from NASDAQ.
Rosetta Genomics Ltd. develops and commercializes diagnostic tests based on microRNAs. The Company has a wholly owned subsidiary, Rosetta Genomics Inc., which serves as the Company's agent for service of process in the United States. Using its intellectual property, collaborative relationships with commercial enterprises and academic and medical institutions in the field of microRNAs, the Company has initiated microRNA-based diagnostic programs for various cancers.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: OTCpicks.com has not been compensated for any stocks listed in this stock news report
